Top Markets
#1 Black Phoenix Black Phoenix +360.67%
#2 Islamic Coin Islamic Coin +158.03%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +56.31%
#5 Akedo Akedo +44.74%
#6 BasedHype BasedHype +32.33%
#7 Acurast Acurast +28.67%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +22.07%
#9 Cryptopia Cryptopia +22.04%
#10 GoPlus Security GoPlus Security +19.42%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Viropro Inc. Viropro Inc.

Viropro Inc.

VPRO
Rank in Stocks #41346
Viropro Inc., a subsidiary of Alpha Biologics Limited, functions as a contract... Viropro Inc., a subsidiary of Alpha Biologics Limited, functions as a contract research and manufacturing organization (CRMO), primarily engaged in the development and production of biotherapeutic proteins aimed at treating diverse medical conditions. The company additionally facilitates the industrial-scale manufacturing of biogeneric therapeutic proteins through the licensing of its proprietary technologies, targeting illnesses like cancer, diabetes, hepatitis, and multiple sclerosis. Viropro manufactures a range of biologics drugs, including biosimilars, for use across all phases of clinical development, from pre-clinical studies through Phase I, II, and III trials. Its offerings to clients include the provision of mammalian cell proteins, such as monoclonal antibodies, recombinant proteins, and other cell-derived compounds. Notably, the firm owns three proprietary clones: two intended for insulin-related therapies and one for cancer treatment. Viropro delivers extensive contractual research and manufacturing solutions to biotech and biopharmaceutical enterprises, performing tasks such as cloning, sequencing, purification, development, validation, and production of biopharmaceutical components and finished products. The company maintains operational presences in Canada, the United Kingdom, and Malaysia, and has established a partnership with Oncobiologics, Inc. for the creation and commercialization of monoclonal antibody products. Viropro Inc. is headquartered in San Jose, California.
Share Price
$0.00002
Last synced: 2026-08-11
Market Cap
$25.40K
Change (1 day)
0.00%
Change (1 year)
-80.00%
Country
US
Trade Viropro Inc. (VPRO)

Category

Healthcare
P/E ratio for Viropro Inc. (VPRO)
P/E ratio as of 2026 TTM: 0
According to Viropro Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Viropro Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.